​

Chemomab Therapeutics Ownership | Who Owns Chemomab Therapeutics?

OverviewForecastChart

Chemomab Therapeutics Ownership Summary

Chemomab Therapeutics is owned by 0.93% institutional investors, 16.73% insiders, and 82.35% retail investors. Orbimed advisors is the largest institutional shareholder, holding 0.21% of CMMB shares.

CMMB Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockChemomab Therapeutics0.93%16.73%82.35%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors940.99K0.21%$1.09M
Sphera funds management738.05K0.16%$856.14K
Yelin lapidot management578.29K0.13%$670.82K
Ikarian capital213.05K0.05%$247.14K
Kestra private wealth services31.24K0.01%$36.24K
Boothbay fund management26.19K0.01%$30.38K
Gamma investing12.81K0.00%$14.86K
Wetzel investment advisors---
Virtu financial---
Two sigma securities---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sphera funds management738.05K0.20%$856.14K
Yelin lapidot management578.29K0.12%$670.82K
Ikarian capital213.05K0.05%$247.14K
Orbimed advisors940.99K0.03%$1.09M
Gamma investing12.81K0.00%$14.86K
Boothbay fund management26.19K0.00%$30.38K
Kestra private wealth services31.24K0.00%$36.24K
Wetzel investment advisors---
Virtu financial---
Two sigma securities---

Top Buyers

HolderShares% AssetsChange
Gamma investing12.81K0.00%1.78K
Kestra private wealth services31.24K0.00%-
Boothbay fund management26.19K0.00%-
Yelin lapidot management578.29K0.12%-
Ikarian capital213.05K0.05%-

Top Sellers

HolderShares% AssetsChange
Orbimed advisors940.99K0.03%-800.28K
Sphera funds management738.05K0.20%-162.38K
Virtu financial---30.80K
Two sigma securities---22.10K
Xtx topco---13.27K

Sold Out

HolderChange
Moser wealth advisors-500.00
Wetzel investment advisors-11.00K
Xtx topco-13.27K
Two sigma securities-22.10K
Virtu financial-30.80K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202514-17.65%4,230,78813.37%-70.20%7-22.22%3-
Mar 31, 2025176.25%3,731,679-10.31%169.98%950.00%3-50.00%
Dec 31, 2024166.67%4,160,723-8.55%176.12%6-40.00%6500.00%
Sep 30, 202415-4,549,76770.23%1148.65%10100.00%1-66.67%
Jun 30, 2024157.14%2,672,7560.42%-106.48%525.00%350.00%

Recent Insider Transactions

DateNameRoleActivityValue
Jan 03, 2023OrbiMed Israel GP Ltd.-Sell$318.06K
Jan 03, 2023OrbiMed Israel GP Ltd.-Sell$889.70K
Jan 03, 2023Mor George Adi Chief Scientific OfficerSell$38.71K
Jan 03, 2023Mor George Adi Chief Scientific OfficerSell$30.66K
Nov 16, 2022Cohen Neil Harris-Sell$4.82K

Insider Transactions Trends

DateBuySell
2023 Q2--
2023 Q1-4
2022 Q4-3
2022 Q22-
2022 Q16-

CMMB Ownership FAQ

Who Owns Chemomab Therapeutics?

Chemomab Therapeutics shareholders are primarily institutional investors at 0.93%, followed by 16.73% insiders and 82.34% retail investors. The average institutional ownership in Chemomab Therapeutics's industry, Biotech Stocks , is 306.59%, which Chemomab Therapeutics falls below.

Who owns the most shares of Chemomab Therapeutics?

Chemomab Therapeutics’s largest shareholders are Orbimed advisors (940.99K shares, 0.21%), Sphera funds management (738.05K shares, 0.16%), and Yelin lapidot management (578.29K shares, 0.13%). Together, they hold 0.49% of Chemomab Therapeutics’s total shares outstanding.

Does Blackrock own Chemomab Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Chemomab Therapeutics.

Who is Chemomab Therapeutics’s biggest shareholder by percentage of total assets invested?

Sphera funds management is Chemomab Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.20% of its assets in 738.05K Chemomab Therapeutics shares, valued at 856.14K$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools